ATE257160T1 - Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde - Google Patents
Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkundeInfo
- Publication number
- ATE257160T1 ATE257160T1 AT98944070T AT98944070T ATE257160T1 AT E257160 T1 ATE257160 T1 AT E257160T1 AT 98944070 T AT98944070 T AT 98944070T AT 98944070 T AT98944070 T AT 98944070T AT E257160 T1 ATE257160 T1 AT E257160T1
- Authority
- AT
- Austria
- Prior art keywords
- proteins
- hinge regions
- medicine
- peptide sequences
- immunoglobulin fragments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9720054.7A GB9720054D0 (en) | 1997-09-19 | 1997-09-19 | Biological products |
PCT/GB1998/002851 WO1999015549A2 (en) | 1997-09-19 | 1998-09-21 | Peptide sequences as hinge regions in proteins like immunoglobulin fragments and their use in medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE257160T1 true ATE257160T1 (de) | 2004-01-15 |
Family
ID=10819407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98944070T ATE257160T1 (de) | 1997-09-19 | 1998-09-21 | Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde |
Country Status (9)
Country | Link |
---|---|
US (1) | US6642356B1 (de) |
EP (1) | EP1015495B1 (de) |
JP (1) | JP4257030B2 (de) |
AT (1) | ATE257160T1 (de) |
AU (1) | AU9174398A (de) |
DE (1) | DE69820885T2 (de) |
ES (1) | ES2212340T3 (de) |
GB (1) | GB9720054D0 (de) |
WO (1) | WO1999015549A2 (de) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
ES2302845T3 (es) * | 2001-10-19 | 2008-08-01 | Zymogenetics, Inc. | Factor de crecimiento dimerizado y materiales y metodos para producirlo. |
GB0303337D0 (en) | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
WO2005000898A2 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
GB0315457D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
JP4833850B2 (ja) | 2003-11-21 | 2011-12-07 | ユセベ ファルマ ソシエテ アノニム | Il−17活性阻害による多発性硬化症を治療するための方法 |
EP1732946B1 (de) * | 2004-03-08 | 2011-07-27 | ZymoGenetics, Inc. | Dimere fusionsproteine und materialien und verfahren zu deren herstellung |
SG173313A1 (en) | 2005-01-05 | 2011-08-29 | Biogen Idec Inc | Cripto binding molecules |
WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
EP1874816A4 (de) | 2005-04-26 | 2010-08-25 | Medimmune Inc | Modulation der antikörpereffektorfunktion mittels manipulation von verbindungsregionen |
EP1926757B1 (de) | 2005-09-14 | 2012-02-22 | UCB Pharma, S.A. | Antikörper-kammpolymer-konjugat |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
TWI417299B (zh) | 2007-03-22 | 2013-12-01 | Biogen Idec Inc | 包括抗體、抗體衍生物及抗體片段之專一性地結合至cd154之結合蛋白及其用途 |
GB0717337D0 (en) | 2007-09-06 | 2007-10-17 | Ucb Pharma Sa | Method of treatment |
ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
EP2475682B1 (de) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Polyvalente antikörper |
GB0916630D0 (en) | 2009-09-22 | 2009-11-04 | Secr Defence | Antibody |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB0920324D0 (en) | 2009-11-19 | 2010-01-06 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
US10472426B2 (en) | 2010-03-25 | 2019-11-12 | Ucb Biopharma Sprl | Disulfide stabilized DVD-Ig molecules |
GB201100282D0 (en) | 2011-01-07 | 2011-02-23 | Ucb Pharma Sa | Biological methods |
US10208349B2 (en) | 2011-01-07 | 2019-02-19 | Ucb Biopharma Sprl | Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy |
EP2565667A1 (de) | 2011-08-31 | 2013-03-06 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Ankunftsrichtungsschätzung mittels mit einem Wasserzeichen versehenen Audiosignalen und Mikrofonanordnungen |
EP2753697A1 (de) | 2011-09-05 | 2014-07-16 | ETH Zürich | Biosynthetischer gencluster zur herstellung von peptid- bzw. protein-analoga |
US9803004B2 (en) | 2011-11-11 | 2017-10-31 | Ucb Biopharma Sprl | Albumin binding antibodies and binding fragments thereof |
EP2880057A4 (de) * | 2012-08-02 | 2016-03-23 | Jn Biosciences Llc | Durch cysteinmutation und ein mu-endstück multimerisierte antikörper oder fusionsproteine |
US11352414B2 (en) | 2014-03-05 | 2022-06-07 | UCB Biopharma SRL | Multimeric Fc proteins |
JP6851322B2 (ja) | 2015-05-27 | 2021-03-31 | ユーシービー バイオファルマ エスアールエル | 神経疾患を治療する方法 |
CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
US20180271998A1 (en) | 2015-12-04 | 2018-09-27 | Merrimack Pharmaceuticals, Inc. | Disulfide-stabilized fabs |
US11266745B2 (en) | 2017-02-08 | 2022-03-08 | Imaginab, Inc. | Extension sequences for diabodies |
CN112004550A (zh) | 2017-12-14 | 2020-11-27 | 康诺贝林伦瑙有限公司 | 用于治疗视神经脊髓炎的重组IgG Fc多聚体 |
GB201804243D0 (en) * | 2018-03-16 | 2018-05-02 | Liverpool School Tropical Medicine | Hinge sequences |
CU20200089A7 (es) | 2018-06-01 | 2021-07-02 | Novartis Ag | Moléculas de unión contra bcma |
JOP20210309A1 (ar) | 2019-05-21 | 2023-01-30 | Novartis Ag | جزيئات ربط بـ cd19 واستخدامتها |
AU2020279224A1 (en) | 2019-05-21 | 2021-12-16 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
EP3972993A1 (de) | 2019-05-21 | 2022-03-30 | Novartis AG | Variante cd58-domänen und deren verwendungen |
US20210040197A1 (en) | 2019-08-08 | 2021-02-11 | Regeneron Pharmaceuticals, Inc. | Novel antigen binding molecule formats |
KR20220062084A (ko) | 2019-09-13 | 2022-05-13 | 체에스엘 베링 렝나우 아게 | 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체 |
JP2022553830A (ja) | 2019-11-05 | 2022-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | N末端scFv多重特異性結合分子 |
BR112022012112A2 (pt) | 2019-12-20 | 2022-09-06 | Regeneron Pharma | Agonistas de il2 e métodos de uso dos mesmos |
EP4126241A1 (de) | 2020-03-27 | 2023-02-08 | Novartis AG | Bispezifische kombinationstherapie zur behandlung proliferativer erkrankungen und autoimmunerkrankungen |
US11673930B2 (en) | 2020-05-12 | 2023-06-13 | Regeneran Pharmaceuticals, Inc. | IL10 agonists and methods of use thereof |
AR123767A1 (es) | 2020-10-13 | 2023-01-11 | Janssen Biotech Inc | Inmunidad mediada por células t mediante bioingeniería, materiales y otros métodos para modular el cúmulo de diferenciación iv y/o viii |
IL302569A (en) | 2020-11-06 | 2023-07-01 | Novartis Ag | CD19 binding molecules and their uses |
CA3199839A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies |
EP4334353A1 (de) | 2021-05-04 | 2024-03-13 | Regeneron Pharmaceuticals, Inc. | Multispezifische fgf21-rezeptoragonisten und deren verwendungen |
WO2023004282A2 (en) | 2021-07-19 | 2023-01-26 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
EP4387988A2 (de) | 2021-08-16 | 2024-06-26 | Regeneron Pharmaceuticals, Inc. | Neue il27-rezeptoragonisten und verfahren zu ihrer verwendung |
WO2023086812A1 (en) | 2021-11-11 | 2023-05-19 | Regeneron Pharmaceuticals, Inc. | Cd20-pd1 binding molecules and methods of use thereof |
WO2023220647A1 (en) | 2022-05-11 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Multispecific binding molecule proproteins and uses thereof |
US20230382969A1 (en) | 2022-05-27 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
WO2023235848A1 (en) | 2022-06-04 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Interleukin-2 proproteins and uses thereof |
US20240067691A1 (en) | 2022-08-18 | 2024-02-29 | Regeneron Pharmaceuticals, Inc. | Interferon receptor agonists and uses thereof |
WO2024040247A1 (en) | 2022-08-18 | 2024-02-22 | Regeneron Pharmaceuticals, Inc. | Interferon proproteins and uses thereof |
WO2024130175A2 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind to aav particles and uses |
WO2024138191A1 (en) | 2022-12-23 | 2024-06-27 | Regeneron Pharmaceuticals, Inc. | Ace2 fusion proteins and uses thereof |
WO2024152014A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
WO2024151978A1 (en) | 2023-01-13 | 2024-07-18 | Regeneron Pharmaceuticals, Inc. | Il12 receptor agonists and methods of use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0284898A3 (de) * | 1987-04-02 | 1990-06-27 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene |
WO1994001451A2 (en) * | 1992-07-13 | 1994-01-20 | Bionebraska, Inc. | Method for modification of recombinant polypeptides |
-
1997
- 1997-09-19 GB GBGB9720054.7A patent/GB9720054D0/en not_active Ceased
-
1998
- 1998-09-21 AU AU91743/98A patent/AU9174398A/en not_active Abandoned
- 1998-09-21 AT AT98944070T patent/ATE257160T1/de not_active IP Right Cessation
- 1998-09-21 WO PCT/GB1998/002851 patent/WO1999015549A2/en active IP Right Grant
- 1998-09-21 ES ES98944070T patent/ES2212340T3/es not_active Expired - Lifetime
- 1998-09-21 US US09/508,930 patent/US6642356B1/en not_active Expired - Fee Related
- 1998-09-21 DE DE69820885T patent/DE69820885T2/de not_active Expired - Fee Related
- 1998-09-21 JP JP2000512854A patent/JP4257030B2/ja not_active Expired - Fee Related
- 1998-09-21 EP EP98944070A patent/EP1015495B1/de not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2212340T3 (es) | 2004-07-16 |
JP4257030B2 (ja) | 2009-04-22 |
AU9174398A (en) | 1999-04-12 |
US6642356B1 (en) | 2003-11-04 |
EP1015495A2 (de) | 2000-07-05 |
GB9720054D0 (en) | 1997-11-19 |
DE69820885T2 (de) | 2004-12-16 |
DE69820885D1 (de) | 2004-02-05 |
WO1999015549A2 (en) | 1999-04-01 |
JP2001517423A (ja) | 2001-10-09 |
EP1015495B1 (de) | 2004-01-02 |
WO1999015549A3 (en) | 1999-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE257160T1 (de) | Peptidsequenzen als scharnierregionen in proteinen wie immunglobulinfragmenten und ihre verwendung in der heilkunde | |
Aggarwal et al. | Human tumor necrosis factor. Production, purification, and characterization. | |
Selsted et al. | Determination of the disulfide array in the human defensin HNP-2: a covalently cyclized peptide | |
Hackeng et al. | Total chemical synthesis of human matrix Gla protein | |
Wilkinson | Troponin C from rabbit slow skeletal and cardiac muscle is the product of a single gene | |
Mann et al. | Solubilization of protein BM‐40 from a basement membrane tumor with cheating agents and evidence for its identity with osteonectin and SPARC | |
AU4162400A (en) | Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii | |
IL152886A0 (en) | B-7 related nucleic acids and polypeptides and pharmaceutical compositions containing the same | |
ES2147558T3 (es) | Nuevos polipeptidos para promover la fijacion celular. | |
NO20005612L (no) | Bindingsmolekyler avledet fra immunoglobuliner som ikke trigger komplementformidlet lysis | |
NZ336929A (en) | Purified receptor that binds TRAIL and antibodies thereof | |
DE69129803D1 (de) | Wasserlösliche peptidanaloguen mit bindungstellen | |
GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
Bentz et al. | Amino acid sequence of bovine osteoinductive factor. | |
Milstein et al. | Disulphide bridges of the heavy chain of human immunoglobulin G2 | |
Araki et al. | The position of the disulfide bonds in human plasma α2HS-glycoprotein and the repeating double disulfide bonds in the domain structure | |
DE69925116D1 (de) | Neue, physiologisch aktive peptide und ihre verwendung. | |
ATE346919T1 (de) | Nebenhoden-spezifisches rezeptorprotein und dessen verwendung | |
DE69832299D1 (de) | Einkettigen polypeptiden enthalten troponin i und troponin c | |
WO1999002708A8 (en) | Fusion proteins comprising sequences derived from bovine if1 atpase inhibitor protein | |
Garcia-Pardo et al. | Primary structure of human plasma fibronectin—characterization of the 6,000 dalton C-terminal fragment containing the interchain disulfide bridges | |
WO2000049038A3 (de) | Synthetische peptide des regulatorischen virusproteins r (vpr) des humanen immundefizienzvirus typ 1 (hiv-1) und ihre verwendung | |
Le-Nguyen et al. | Design and chemical synthesis of a 32 residues chimeric microprotein inhibiting both trypsin and carboxypeptidase A | |
Pomroy et al. | Conjugation of polyethylene glycol via a disulfide bond confers water solubility upon a peptide model of a protein transmembrane segment | |
DE69533545D1 (de) | Faltende proteine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1015495 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |